Plasma Protein Therapeutics Market by Product Type (C1 esterase Inhibitors, Albumins, Immunoglobulin’s & Coagulation Factors), by Application Type (Hereditary Angioedema, Hemophilia, Primary Immunodeficiency Disorder) - Global Industry Analysis, Trends and Forecast 2023-2028
The global Plasma Protein Therapeutics Market is expected to exceed US$ 38.40 Billion by 2028, with CAGR at 7.5 % in the given forecast period.
COVID-19 Impact Analysis Report
Infopedia: Access Our All Reports Online at Affordable Price
CLICK HEREMARKET SNAPSHOT
Major Players
Study period:
Fastest Growing Market:
2023-2028
APAC
Base Year:
Largest Market:
2022
North America
CAGR:
7
REPORT DESCRIPTION
Plasma is the liquid parts of blood that residue once platelets, white and red blood cells and various other cellular components are detached. In human blood only plasma is largest component and contains proteins, antibodies, enzymes, salts and water. Plasma is the protein rich fluids that defer cells in human blood and achieves various essential transport functions. The proteins that originate in plasma plays important function in clotting and provide immunity to diseases. Plasma proteins are used in many conditions for treatment such as shocks & burns, neurological & bleeding disorders, autoimmune and immune deficiencies.
Plasma protein therapies is a unique biological medicine which contains biological starting material called plasma which have unique bio chemical profile which differs in processing methods and production methods. Plasma protein therapies are used to treat various genetic, chronic, life threatening and rare diseases.
The global Plasma Protein Therapeutics Market is expected to exceed US$ 38.40 Billion by 2028, with CAGR at 7.5 % in the given forecast period.
The plasma protein therapeutics market is segmented on the lines of its product type, application and regional. Under product type segmentation it covers C1 esterase inhibitors, albumins, immunoglobulin’s and coagulation factors. Based on application segmentation the plasma protein therapeutics covers hereditary angioedema, hemophilia, primary immune deficiency disorder, secondary immune deficiency, idiopathic thrombocytopenic and others such as Kawasaki disease, GBS, CIDP etc.The plasma protein therapeutics market's geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographical region market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for plasma protein therapeutics and related technologies.
2) Analyses of global market trends, with data from 2019, estimates for 2020 and 2021, and projections of compound annual growth rates (CAGRs) through 2027.
3) Identifications of new market opportunities and targeted promotional plans for plasma protein therapeutics.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets .The reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire Plc. and China Biologics. CSL Behring is the market leader in the plasma protein therapeutics market, while GRIFOLS, S.A leads the global market for IVIG and Alpha 1 antitrypsin. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Plasma Protein Therapeutics Market has been segmented as below:
By Product Type Analysis
C1 esterase Inhibitors
Albumins
Immunoglobulins
Coagulation Factors
Others
By Application Analysis
Hereditary Angioedema
Hemophilia
Primary Immunodeficiency Disorder
Secondary Immunodeficiency
Idiopathic Thrombocytopenic
Others (Kawasaki disease, GBS, CIDP etc)
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
Reasons to Buy this Report:
1. Obtain the most up to date information available on all plasma protein therapeutics market.
2. Identify growth segments and opportunities in the industry.
3. Facilitate decision making on the basis of strong historic and forecast of plasma protein therapeutics market data.
4. Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
drug delivery technology market
Drug Discovery Informatics Market
chapter 1 INTRODUCTION
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
Chapter 2 Executive Summary
2.1 Global Plasma Protein Therapeutics Market Snapshot
Chapter 3 Global Plasma Protein Therapeutics Market Revenue Analysis, 2023–2028 (US$ Mn)
3.1 Introduction
3.2 Regulatory Scenario
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunity
3.4 Market Attractiveness Analysis, by Region, 2015
3.5 Porter’s Five Forces Analysis
3.6 Global Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2023–2028 (US$ Mn)
3.6.1 Global Immunoglobulins Market Revenue, 2023–2028 (US$ Mn)
3.6.2 Global Albumin Market Revenue, 2023–2028 (US$ Mn)
3.6.3 Global Coagulation Factors Market Revenue, 2023–2028 (US$ Mn)
3.6.4 Global C1-esterase Inhibitors Market Revenue, 2023–2028 (US$ Mn)
3.6.5 Others (e.g. Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins)
3.7 Global Plasma Protein Therapeutics Market Analysis, By Application, 2023–2028 (US$ Mn)
3.7.1 Global Hemophilia Market Revenue, 2023–2028 (US$ Mn)
3.7.2 Global Primary Immunodeficiency Disorder (PID) Market Revenue, 2023–2028 (US$ Mn)
3.7.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2023–2028 (US$ Mn)
3.7.4 Global Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2015–2025 (US$ Mn)
3.7.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
3.8 Competitive Landscape
3.8.1 Market Positioning of Key Players, 2015
3.8.2 Recommendations
3.9 Pipeline Analysis
3.9.1 Phase 1 and Phase 2 Drugs (Qualitative Analyses)
3.9.2 Phase 3 and Phase 4 Drugs (Quantitative), Forecasts till 2025
Chapter 4 North America Plasma Protein Therapeutics Market Revenue Analysis, 2023–2028 (US$ Mn)
4.1 North America Plasma Protein Therapeutics Market Revenue, By Product Type, 2023–2028 (US$ Mn)
4.1.1 North America Immunoglobulins Market Revenue, 2023–2028 (US$ Mn)
4.1.2 North America Albumin Market Revenue, 2023–2028 (US$ Mn)
4.1.3 North America Coagulation Factors Market Revenue, 2023–2028 (US$ Mn)
4.1.4 North America C1-esterase Inhibitors Market Revenue, 2023–2028 (US$ Mn)
4.1.5 Others
4.2 North America Plasma Protein Therapeutics Market Revenue, By Application, 2023–2028 (US$ Mn)
4.2.1 North America Hemophilia Market Revenue, 2023–2028 (US$ Mn)
4.2.2 North America Primary Immunodeficiency Disorder (PID) Market Revenue, 2023–2028 (US$ Mn)
4.2.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2023–2028 (US$ Mn)
4.2.4 North America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2023–2028 (US$ Mn)
4.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
4.3 North America Plasma Protein Therapeutics Market Revenue, by Country 2023–2028 (US$ Mn)
Chapter 5 Europe Plasma Protein Therapeutics Market Revenue, 2023–2028 US$ Mn)
5.1 Europe Plasma Protein Therapeutics Market Revenue, By Product Type, 2023–2028 (US$ Mn)
5.1.1 Europe Immunoglobulins Market Revenue, 2023–2028 (US$ Mn)
5.1.2 Europe Albumin Market Revenue, 2023–2028 (US$ Mn)
5.1.3 Europe Coagulation Factors Market Revenue, 2023–2028 (US$ Mn)
5.1.4 Europe C1-esterase Inhibitors Market Revenue, 2023–2028 (US$ Mn)
5.1.5 Others
5.2 Europe Plasma Protein Therapeutics Market Revenue, By Application, 2023–2028 (US$ Mn)
5.2.1 Europe Hemophilia Market Revenue, 2023–2028 (US$ Mn)
5.2.2 Europe Primary Immunodeficiency Disorder (PID) Market Revenue, 2023–2028 (US$ Mn)
5.2.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2023–2028(US$ Mn)
5.2.4 Europe Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2023–2028 (US$ Mn)
5.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
5.3 Europe Plasma Protein Therapeutics Market Revenue, by Country, 2023–2028 (US$ Mn)
Chapter 6 Asia Pacific Plasma Protein Therapeutics Market Revenue Analysis, 2023–2028 (US$ Mn)
6.1 Asia Pacific Plasma Protein Therapeutics Market Revenue, By Product Type, 2023–2028 (US$ Mn)
6.1.1 Asia Pacific Immunoglobulins Market Revenue, 2023–2028 (US$ Mn)
6.1.2 Asia Pacific Albumin Market Revenue, 2023–2028 (US$ Mn)
6.1.3 Asia Pacific Coagulation Factors Market Revenue, 2023–2028 (US$ Mn)
6.1.4 Asia Pacific C1-esterase inhibitors Market Revenue, 2023–2028 (US$ Mn)
6.1.5 Others
6.2 Asia Pacific Plasma Protein Therapeutics Market Revenue, By Application, 2023–2028 (US$ Mn)
6.2.1 Asia Pacific Hemophilia Market Revenue, 2023–2028 (US$ Mn)
6.2.2 Asia Pacific Primary Immunodeficiency Disorder (PID) Market Revenue, 2023–2028 (US$ Mn)
6.2.3 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2023–2028 (US$ Mn)
6.2.4 Asia Pacific Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2023–2028 (US$ Mn)
6.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
6.3 Asia Pacific Plasma Protein Therapeutics Market by Geography, Market Revenue, 2023–2028 (US$ Mn)
Chapter 7 Latin America Plasma Protein Therapeutics Revenue Analysis, 2023–2028 (US$ Mn)
7.1 Latin America Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2023–2028 (US$ Mn)
7.1.1 Latin America Immunoglobulins Market Revenue, 2023–2028 (US$ Mn)
7.1.2 Latin America Albumin Market Revenue, 2023–2028 (US$ Mn)
7.1.3 Latin America Coagulation Factors Market Revenue, 2023–2028 (US$ Mn)
7.1.4 Latin America C1-esterase Inhibitors Market Revenue, 2023–2028 (US$ Mn)
7.1.5 Others
7.2 Latin America Plasma Protein Therapeutics Market Revenue, By Application, 2023–2028 (US$ Mn)
7.2.1 Latin America Hemophilia Market Revenue, 2023–2028 (US$ Mn)
7.2.2 Latin America Primary Immunodeficiency Disorder (PID) Market Revenue, 2023–2028 (US$ Mn)
7.2.3 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2023–2028 (US$ Mn)
7.2.4 Latin America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2023–2028 (US$ Mn)
7.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
7.3 Latin America Plasma Protein Therapeutics Market by Geography, Market Revenue, 2023–2028 (US$ Mn)
Chapter 8 Rest of the World (RoW) Plasma Protein Therapeutics Market Revenue Analysis, 2023–2028 (US$ Mn)
8.1 Rest of World Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2023–2028 (US$ Mn)
8.2 Rest of World Plasma Protein Therapeutics Market Revenue, By Application, 2023–2028 (US$ Mn)
Chapter 9 Company Profiles
9.1 Baxter International
9.1.1 Company Overview
9.1.2 Product Portfolio
9.1.3 Financial Overview
9.1.4 Business Strategies
9.1.5 Recent Development
9.2 Biotest
9.2.1 Company Overview
9.2.2 Product Portfolio
9.2.3 Financial Overview
9.2.4 Recent Development
9.3 CSL Behring
9.3.1 Company Overview
9.3.2 Product Portfolio
9.3.3 Financial Overview
9.3.4 Business Strategies
9.3.5 Recent Development
9.4 China Biologics
9.4.1 Company Overview
9.4.2 Product Portfolio
9.4.3 Financial Overview
9.4.4 Business Strategies
9.4.5 Recent Development
9.5 GRIFOLS, S.A.
9.5.1 Company Overview
9.5.2 Product Portfolio
9.5.3 Financial Overview
9.5.4 Business Strategies
9.5.5 Recent Development
9.6 Kedrion
9.6.1 Company Overview
9.6.2 Product Portfolio
9.6.3 Financial Overview
9.6.4 Recent Development
9.7 Octapharma USA, Inc.
9.7.1 Company Overview
9.7.2 Product Portfolio
9.7.3 Financial Overview
9.7.4 Recent Development
9.8 Shire Plc.
9.8.1 Company Overview
9.8.2 Product Portfolio
9.8.3 Financial Overview
9.8.4 Business Strategies
9.8.5 Recent Development
The Plasma Protein Therapeutics Market has been segmented as below:
By Product Type Analysis
C1 esterase Inhibitors
Albumins
Immunoglobulins
Coagulation Factors
Others
By Application Analysis
Hereditary Angioedema
Hemophilia
Primary Immunodeficiency Disorder
Secondary Immunodeficiency
Idiopathic Thrombocytopenic
Others (Kawasaki disease, GBS, CIDP etc)
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
Got a question? We've got answers. If you have some other questions, see our support center.
© 2020 COPYRIGHT : MARKET RESEARCH ENGINE